G-Protein Coupled Receptors Market 2024 - By Industry Share, Growth Analysis, Technological Innovations, Opportunities, New Business Strategies And Forecast To 2033

The Business Research Company recently released a comprehensive report on the Global G-Protein Coupled Receptors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11976&type=smp

According to The Business Research Company's, The g-protein coupled receptors market size has grown strongly in recent years. It will grow from $2.97 billion in 2023 to $3.18 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to drug discovery advances, fda approvals, genomic discoveries, emerging markets, market consolidation, growing aging population.

The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine, increased focus on rare diseases, artificial intelligence in drug discovery, patient-centric drug development, environmental and social factors, biosimilar market growth. Major trends in the forecast period include biotechnology advancements, increased r&d investment, technological innovations, collaborations and partnerships, digital therapeutics.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report

Market Drivers and Trends:

The rising prevalence of cancer is expected to propel the growth of the G-protein-coupled receptors market going forward. Cancer is an illness in which abnormal cells can infect surrounding tissues and spread uncontrollably. The lymphatic and vascular systems of the body are further routes by which cancer cells might spread. GPCRs control the processes identified as the defining characteristics of cancer, including proliferative signaling, replicative immortality, evasion of growth suppressors, resistance to apoptosis, and the activation of invasion and metastasis. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization working for cancer care, in the United States, kidney cancer will be discovered in 81,800 individuals in 2023 (52,360 males and 29,440 women. Furthermore, in April 2022, Breast cancer surpassed lung cancer to become the most commonly diagnosed cancer worldwide, affecting an estimated 2.3 million women in 2021 alone, according to the Breast Cancer Research Foundation, a US-based not-for-profit organization in breast cancer for clinical and translational research. In the United States, where breast cancer has been the most frequent cancer for many years, 281,550 women are expected to be diagnosed in 2021 Therefore, the rising prevalence of cancer is driving the growth of the G-protein coupled receptors market.

Investment to advance GPCR screening and antibody development is a key trend gaining popularity in the G-protein-coupled receptor (GPCR) market. Major companies operating in GPCR are focusing on attaining investment for developing drugs and medication technologies related to GPCR-driven diseases. For instance, in February 2023, LifeArc Ventures, a UK-based venture capital firm, invested $16 million in Maxion Therapeutics, a UK-based drug discovery company, to advance antibody development for previously untreatable ion channel and GPCR-driven disorders. This funding will enable the development of antibody therapeutics targeting ion channels and G-protein-coupled receptors (GPCRs) using the proprietary KnotBody technology. The KnotBody platform enables the discovery of biologicals against ion channels and GPCRs, using naturally occurring cysteine-rich mini proteins. Moreover, Septerna Inc., a US-based biotechnology company, announced its launch and Series A financing of $100 million. This Series A funding will be used for developing its emerging pipeline of innovative GPCR-targeted medication programs powered by the Native Complex Platform and covering numerous therapeutic areas.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Danaher Corporation, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Thermo Fisher Scientific Inc., Perkin Elmer Inc., Qiagen N.V., Bio-Techne Corporation, Abcam PLC, Cara Therapeutics Inc., Sosei Heptares Ltd., Eurofins DiscoverX Corporation, Crinetics Pharmaceuticals Inc., Domain Therapeutics SA, Addex Pharmaceuticals Ltd., Escient Pharmaceuticals Inc., Structure Therapeutics, Septerna

G-Protein Coupled Receptors Market 2024 Key Insights:

• The g-protein coupled receptors market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%.
• G-Protein-Coupled Receptors Market Poised For Growth Driven By Escalating Cancer Prevalence
• Lifearc Ventures Backs Maxion Therapeutics And Septerna Inc. To Propel G-Protein-Coupled Receptor Research
• North America was the largest region in the G-protein coupled receptors market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=11976&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.